Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
The role of patent analysis in target selection74
FAK inhibitors in cancer, a patent review – an update on progress38
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)34
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)32
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities32
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)32
Update on mGlu4 modulator patents: 2017 to present27
T-type calcium channel blockers: a review of recent advances (2018–2025)26
Recent developments of agents targeting Vibrio cholerae : patents and literature data26
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)26
Caspase inhibitors: a review on recently patented compounds (2016–2023)25
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present25
An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020–present)25
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
An updated patent review of AKT inhibitors (2020 – present)22
A patent review of MAPK inhibitors (2018 – present)20
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review20
Inhibition of GTPase KRAS G12D : a review of patent literature19
An update on PDGFR inhibitors: a patent review (2020 - present)18
A patent review of LPAR1 antagonists (2010 – present)18
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)18
Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)18
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202318
Antiprotozoal drugs: challenges and opportunities18
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)18
A patent review of IDH1 inhibitors (2018-present)17
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)17
Small-molecule RNA ligands: a patent review (2018–2024)17
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)17
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present)16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)16
An updated patent review of MALT1 inhibitors (2021–present)16
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
Novel fatty acid amide hydrolase (FAAH) inhibitors: a patent review from 2015 to 202515
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature15
Antimalarial drugs: what’s new in the patents?15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
A patent and literature review of CDK12 inhibitors15
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders15
Biofilm and bacterial membrane vesicles: recent advances15
Are patents important indicators of innovation for Chagas disease treatment?14
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)14
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)14
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes14
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs14
An updated patent review of EZH2 inhibitors (2024–present)14
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
A patent review of NLRP3 inhibitors to treat autoimmune diseases14
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review13
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
Recent patent landscape of ASK1 inhibitors: spotlight on 2-(1-isopropyl-4H-1,2,4-triazole-3-yl) pyridine as a privileged scaffold13
Biomedical applications of prokaryotic carbonic anhydrases: an update12
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa12
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)12
Sirtuin modulators: a review of patents from 2020 to 202412
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience12
Correction12
An updated patent review of TRPA1 antagonists (2020 – present)12
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)12
The patent review of the biological activity of tropane containing compounds12
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)11
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)11
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)11
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress11
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity11
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted11
5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present)11
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)10
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)10
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)10
A patent review of selective CDK9 inhibitors in treating cancer9
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)9
An updated patent review of isoflavones and isocoumarins (2018–2024)9
A patent review of CXCR7 modulators (2019-present)9
A patent review of DNA polymerase theta (Polθ) targeted therapies (2019–2025)9
Impact of patent-granting differences between Japan and the United States on patent protection for medical methods: insights from genome editing patents9
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)9
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)9
A patent review of BRD4 inhibitors (2020–present)9
Rho kinase inhibitors: a patent review (2017–2023)9
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published9
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)9
A patent perspective of antiangiogenic agents8
Nurr1 modulators – a patent review (2019–present)8
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents8
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid8
Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019–2024)8
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
Recent advances in the development of STING inhibitors: an updated patent review8
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)8
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20238
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update8
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)8
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)8
Therapeutic cysteine protease inhibitors: a patent review (2018–present)8
Patents involving monoamine oxidase (MAO): a comprehensive update (2022–2025) on its inhibitors and applications8
Patent landscape of small molecule inhibitors of METTL3 (2020-present)8
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)8
Pitfalls in patenting academic CAR-T cells therapy7
An updated patent review of Mcl-1 inhibitors (2020–2022)7
A patent review of xanthine oxidase inhibitors (2021–present)7
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)7
An updated patent review of glutaminase inhibitors (2019–2022)7
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)7
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective7
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)7
An updated patent review of stimulator of interferon genes agonists (2021 – present)6
A patent review of VEGFR-2 inhibitors: an update (2022 – present)6
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)6
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)6
Natural products as a source of new anticancer chemotypes6
Anticancer drugs: where are we now?6
An updated patent review of BRD4 degraders6
Proteasome inhibitors as anticancer agents6
Small molecule agonists of Toll-like receptors 7 and 8: an updated patent review 2021 – 20256
Coactivator-associated arginine methyltransferase 1 (CARM1) inhibitors: a patenting perspective (2018-present)6
A review of the patent literature surrounding TRPV1 modulators6
Myeloperoxidase (MPO) inhibitors: an updated patent review (2020 - present)6
A patent review of IDO1 inhibitors for cancer (2023 – present): an update6
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)6
PIM kinase inhibitors: an updated patent review (2016-present)5
Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with in vitro activity against Acinetobacter b5
BET inhibitors: an updated patent review (2018–2021)5
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)5
CDC7 kinase inhibitors: a survey of recent patent literature (2017–2022)5
Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)5
CBL-B – An upcoming immune-oncology target5
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)5
A patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2022-present): an update5
A patent review of CHK1 inhibitors (2019 – present)5
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections5
An updated review of discoidin domain receptor 1 (DDR1) modulators (2020-present)5
A patent review of MLKL modulators (2023 – present)5
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326155
Update on JNK inhibitor patents: 2015 to present5
Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021–2024)5
0.054164886474609